On March 3, 2025, WuXi AppTec announced that it had completed the sale of its U.S. medical device testing operations to NAMSA. Wilson Sonsini is pleased to have represented WuXi AppTec throughout this transaction.

WuXi AppTec is a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries.

The Wilson Sonsini team that advised WuXi AppTec on the completion of the transaction includes:

Corporate/M&A
Weiheng Chen
Jie Zhu
Chun Teng
Yang Liao
Yi Shen

Employee Benefits and Compensation
Michael Klippert
Mark Cornillez-Ty
Jason Chan

Employment and Trade Secret Litigation 
Matt Gorman
Quinn Christie

Environmental
Martin Sul

FDA Regulatory
Eva Yin

Real Estate
James McCann
Moncarol Wang

Tax
Myra Sutanto Shen

Technology Transactions – Biotech
John Wehrli
Taylor Arterburn
James Dunlop

Technology Transactions – IT
Barath Chari
Rodrigo Valle

For more information on the transaction, please see our client highlight announcing the deal and WuXi AppTec’s press release announcing the completion of the transaction.